Last quarter (Q4 2022), PYC Therapeutics Limited's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, PYC Therapeutics Limited's net income was $―. See PYC Therapeutics Limited’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19	Jun 18
Total Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Operating Expense	$ ―	$ 30.21M	$ 21.83M	$ 9.74M	$ 7.10M	$ 9.77M
Operating Income	$ ―	$ -30.21M	$ -21.83M	$ -9.74M	$ -7.10M	$ -9.77M
Net Non Operating Interest Income Expense	$ ―	$ -8.17K	$ 69.68K	$ 207.03K	$ 117.96K	$ 114.88K
Other Income Expense	$ ―	$ 15.92M	$ 3.13M	$ 62.50K	$ 250.00	$ 48.46K
Pretax Income	$ ―	$ -14.29M	$ -18.63M	$ -9.48M	$ -6.98M	$ -9.60M
Tax Provision	$ ―	$ 0.00	$ 0.00	$ -2.40M	$ -2.90M	$ -2.17M
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -13.86M	$ -17.77M	$ -6.82M	$ -4.08M	$ -7.43M
Basic EPS	$ ―	$ >-0.01	$ >-0.01	$ >-0.01	$ >-0.01	$ ―
Diluted EPS	$ ―	$ >-0.01	$ >-0.01	$ >-0.01	$ >-0.01	$ ―
Basic Average Shares	$ ―	$ 3.18B	$ 3.09B	$ 2.64B	$ 2.40B	$ ―
Diluted Average Shares	$ ―	$ 3.18B	$ 3.09B	$ 2.64B	$ 2.40B	$ ―
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income From Continuing And Discontinued Operation	$ ―	$ -13.86M	$ -17.77M	$ -6.82M	$ -4.08M	$ -7.43M
Normalized Income	$ ―	$ -13.86M	$ -17.77M	$ -6.82M	$ -4.08M	$ -7.43M
Interest Expense	$ ―	$ 32.59K	$ 38.82K	$ ―	$ ―	$ ―
EBIT	$ ―	$ -14.26M	$ -18.59M	$ -9.74M	$ -7.10M	$ -9.77M
EBITDA	$ ―	$ -13.42M	$ -17.97M	$ -9.20M	$ -6.97M	$ -9.69M

Currency in USD

PYC Therapeutics Limited Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing